165 related articles for article (PubMed ID: 12431973)
1. BRCA1/2 genetic testing in the community setting.
Chen WY; Garber JE; Higham S; Schneider KA; Davis KB; Deffenbaugh AM; Frank TS; Gelman RS; Li FP
J Clin Oncol; 2002 Nov; 20(22):4485-92. PubMed ID: 12431973
[TBL] [Abstract][Full Text] [Related]
2. Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.
Lheureux S; Karakasis K; Harter P; Scott C; Bacon M; Bryce J; Le Fur N; Pujade-Lauraine E; Oza AM
Gynecol Oncol; 2016 Jan; 140(1):90-4. PubMed ID: 26475959
[TBL] [Abstract][Full Text] [Related]
3. Patient satisfaction of BRCA1/2 genetic testing by women at high risk for breast cancer participating in a prevention trial.
Klemp JR; O'Dea A; Chamberlain C; Fabian CJ
Fam Cancer; 2005; 4(4):279-84. PubMed ID: 16341803
[TBL] [Abstract][Full Text] [Related]
4. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
5. Interest in BRCA1/2 testing in a primary care population.
Armstrong K; Weber B; Ubel PA; Guerra C; Schwartz JS
Prev Med; 2002 Jun; 34(6):590-5. PubMed ID: 12052018
[TBL] [Abstract][Full Text] [Related]
6. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
[TBL] [Abstract][Full Text] [Related]
7. Familial breast and ovarian cancers.
Arai M; Utsunomiya J; Miki Y
Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
[TBL] [Abstract][Full Text] [Related]
8. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
9. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
10. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
11. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.
Lerman C; Biesecker B; Benkendorf JL; Kerner J; Gomez-Caminero A; Hughes C; Reed MM
J Natl Cancer Inst; 1997 Jan; 89(2):148-57. PubMed ID: 8998184
[TBL] [Abstract][Full Text] [Related]
12. Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.
Armstrong J; Toscano M; Kotchko N; Friedman S; Schwartz MD; Virgo KS; Lynch K; Andrews JE; Aguado Loi CX; Bauer JE; Casares C; Bourquardez Clark E; Kondoff MR; Molina AD; Abdollahian M; Walker G; Sutphen R
JAMA Oncol; 2015 Dec; 1(9):1251-60. PubMed ID: 26426480
[TBL] [Abstract][Full Text] [Related]
13. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
[TBL] [Abstract][Full Text] [Related]
14. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with decisions about clinical BRCA1/2 testing.
Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
[TBL] [Abstract][Full Text] [Related]
17. Referral and experience with genetic testing among women with early onset breast cancer.
Brown KL; Hutchison R; Zinberg RE; McGovern MM
Genet Test; 2005; 9(4):301-5. PubMed ID: 16379543
[TBL] [Abstract][Full Text] [Related]
18. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
[TBL] [Abstract][Full Text] [Related]
19. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study.
Reedy M; Gallion H; Fowler JM; Kryscio R; Smith SA
Gynecol Oncol; 2002 May; 85(2):255-9. PubMed ID: 11972384
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of BRCA1 and BRCA2 mutations in male breast cancer patients in Canada.
Wolpert N; Warner E; Seminsky MF; Futreal A; Narod SA
Clin Breast Cancer; 2000 Apr; 1(1):57-63; discussion 64-5. PubMed ID: 11899391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]